Drugs · acquisition-cost intelligence
EPIPEN
epinephrine· ingredient epinephrineAdrenergic and dopaminergic agents· EPINEPHRINE .15 mg/.3mL; EPINEPHRINE .3 mg/.3mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$141.60
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-03-192026-05-20
Same-ingredient options by acquisition cost
Other epinephrine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| epinephrine | $1.19 | −$140.40 |
| Epinephrine Pediatrics | $116.61 | −$24.98 |
| Auvi-Q | $297.73 | +$156.13 |
Medicare Part D coverage · CY2026
On 324 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 56% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.